Brandt; Ralf

Patent Applications and Registrations

Patent applications and USPTO patent grants for Brandt; Ralf.The latest application filed is for "pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from ".

Company Profile

2.6.10

Brandt; Ralf - Greenwith AU
Brandt; Ralf - Camberwell Victoria
Brandt; Ralf - Farnborough GB
Brandt, Ralf - Adelaide AU

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Pharmaceutical Composition for Treating Cancer Comprising Trypsinogen and/or Chymotrypsinogen and an Active Agent Selected from App 20190388463 - Kenyon; Julian Norman ; et al.	2019-12-26
Proenzyme Composition App 20190262435 - Kenyon; Julian ; et al.	2019-08-29
Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent Grant 10,350,239 - Kenyon , et al. July 16, 2	2019-07-16
Composition of proenzymes for cancer treatment App 20190134166 - Kenyon; Julian ; et al.	2019-05-09
Pharmaceutical Composition For Treating Cancer Comprising Trypsinogen And/or Chymotrypsinogen And An Active Agent Selected From A Selenium Compound, A Vanilloid Compound And A Cytoplasmic Glycolysis Reduction Agent App 20180064753 - Kenyon; Julian Norman ; et al.	2018-03-08
Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent Grant 9,636,359 - Kenyon , et al. May 2, 2	2017-05-02
Method of configuring FM radio transmitters in portable devices Grant 8,571,576 - Brandt , et al. October 29, 2	2013-10-29
Pharmaceutical Composition For Treating Cancer Comprising Trypsinogen And/or Chymotrypsinogen And An Active Agent Selected From A Selenium Compound, A Vanilloid Compound And A Cytoplasmic Glycolysis Reduction Agent App 20120251516 - Kenyon; Julian Norman ; et al.	2012-10-04
Processor, Apparatus and Associated Methods App 20120225669 - Brandt; Seemal ; et al.	2012-09-06
Combination comprising a signal transduction inhibitor and an epothilone derivative Grant 7,723,339 - Brandt , et al. May 25, 2	2010-05-25
Combination comprising an agent decreasing VEGF activity and an agent decreasing EGF activity App 20060270665 - Wood; Jeanette Marjorie ; et al.	2006-11-30
Tumor model App 20050214220 - Brandt, Ralf	2005-09-29
Combination comprising a signal transduction inhibitor and an epothilone derivative App 20040132754 - Brandt, Ralf ; et al.	2004-07-08
Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity App 20040034026 - Wood, Jeannette M ; et al.	2004-02-19

Company Registrations

SEC

0001715437

Brandt Ralf

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.